Loteprednol .5% And .2% Solutions Clear FDA: Bausch & Lomb To Market
Executive Summary
Bausch & Lomb's Lotemax (loteprednol) will be available in four to six weeks, carrying "the broadest range of indications of any ophthalmic steroid on the market," including post-operative inflammation, the company said.